Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology

Wednesday, February 6, 2008 General News J E 4
NAPA, Calif., Feb. 5 Senetek PLC(OTC Bulletin Board: SNKTY), a Life Sciences company engaged in thedevelopment of technologies that target the science of healthy aging, todayannounced the debut of Pyratine-6(TM) at the 66th Annual Meeting of theAmerican Academy of Dermatology in San Antonio, Texas.

Pyratine-6(TM), Senetek's exclusive second generation cytokinin, has beenclinically proven to be effective in correcting visible signs of skin agingand significantly reducing erythema as early as two weeks from onset of use.

The Annual Meeting of the American Academy of Dermatology runs fromFebruary 1 - 5, 2008. Approximately 7,000 medical personnel are registered toattend.

Commenting on the debut, Mr. Frank Massino, Senetek's Chairman and ChiefExecutive Officer stated, "We are delighted to see this compelling therapeuticcome to the market and are very pleased by the reception Pyratine-6(TM) hasreceived from dermatologists at this important conference. Pyratine-6(TM) hasbeen successfully clinically tested and has shown attributes more beneficialto treatment than any predecessor compound."

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engagedin the development of breakthrough technologies that target the science ofhealthy aging. The Company's extensive research collaborations have resultedin a strong pipeline of patented compounds and products with broad therapeuticapplications and a leading presence in dermatology. Senetek collaborates withestablished specialty pharmaceutical companies in the final development andmarketing of its proprietary products, most recently resulting in thedevelopment of the best-selling anti-aging product sold in the North Americanphysician market.

For more information, visit the company's website at

This news release contains statements that may be considered'forward-looking statements' within the meaning of the Private SecuritiesLitigation Reform Act. Forward-looking statements by their nature involvesubstantial uncertainty, and actual results may differ materially from thosethat might be suggested by such statements. Important factors identified bythe Company that it believes could result in such material differences aredescribed in the Company's Annual Report on Form 10-K for the year 2006.However, the Company necessarily can give no assurance that it has identifiedor will identify all of the factors that may result in any particularforward-looking statement materially differing from actual results, and theCompany assumes no obligation to correct or update any forward-lookingstatements which may prove to be inaccurate, whether as a result of newinformation, future events or otherwise.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
CVS Caremark Charitable Trust Awards $5.5 Million ...
Leading Network of Aesthetic Service Providers Off...